Skip to content

About Avicanna


Avicanna is a Canadian commercial-stage biopharmaceutical company established in research, development, and commercialization of evidence-based cannabinoid products for the global medical and pharmaceutical market segments.

Avicanna has established an industry leading scientific platform that has led to commercialization of 30+ proprietary cannabinoid based products in addition to a robust pharmaceutical pipeline.

Market Segments

Serving the Global Marketplace with Proprietary Advanced Cannabinoid-Based Products

Commercial Products & Pipeline

Avicanna’s scientific platform has resulted in 30+ commercial and proprietary formulations and products
Including medical cannabis, wellness, and its pharmaceutical pipeline

Commercial Stage
Medical Cannabis
Pharmacy Platform

Commercial Stage 
Medical Cannabis
Wellness Products

In Development and Registration Stage
Pharmaceutical Pipeline


Medical Cannabis & Wellness Products

Marketed under the RHO Phyto™ brand

The portfolio contains a diverse range of formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids such as cannabidiol (“CBD”), cannabigerol (“CBG”), and tetrahydrocannabinol (“THC”).

The formulary is supported by ongoing consumer, patient, and medical community education and training including

The brand is currently available nationwide to patients in medical channels across Canada including launched August 2023. It is also accessible through several other medical institutions including The University Health Network (“UHN”) and the Odette Cancer Centre pharmacy of Sunnybrook Health Science Centre, a major hospital group in Canada. The products are also found in Canadian adult-use sales channels through provincial retailers in five provinces including Ontario, Alberta, British Columbia, New Brunswick, Manitoba, and Saskatchewan.


Pharmaceutical Preparation and Pipeline of Proprietary Drug Candidates

Pharmaceutical candidates designed to address 5 major clinical indications

Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of indication-specific drug candidates that are in various stages of clinical development, registration, and commercialization.

These cannabinoid-based drug candidates are designed to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders.

3 Medical Cannabis Care Platform is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the patient journey. is operated by Northern Green Canada Inc. under an agreement and features diverse portfolio of products and a pharmacist led patient support groups such as veterans and collaborating with public and private providers for adjudication and reimbursement and educational resources to facilitate the incorporation of medical cannabis into health care regimes.

Scientific Platform

Industry leading scientific platform and intellectual property

Scientific Platform

Setting the Standard in the cannabinoid industry with advanced and evidence based products 

R&D headquarters in Toronto, Canada with drug development pipeline including sustained release tablets, transdermal patches and nano particle formulations.


Proprietary Commercial Products




Canadian Government Research Grants Awarded Since 2020


Pending Patents


Health Canada Cannabis
Research Licenses
to Avicanna
or Institutional Collaborators